Pembrolizumab shows promise in relapsed/refractory multiple myeloma

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In patients with relapsed/refractory multiple myeloma (RRMM), pembrolizumab (Keytruda) + pomalidomide (Pomalyst) + low-dose dexamethasone was well-tolerated and delivered an encouraging and durable response.

Why this matters

  • These results follow the recent US Food and Drug ...